InMed Pharmaceuticals Inc. 8-K

What Happened
InMed Pharmaceuticals Inc. announced on April 3, 2026 that it filed a prospectus supplement and related prospectus with the SEC to permit the sale of its common shares under an existing At-The-Market (ATM) Sales Agreement with H.C. Wainwright & Co., LLC. The prospectus supplement is made pursuant to the company’s shelf registration statement on Form S-3 (File No. 333-294503), which the SEC declared effective on March 30, 2026.

Key Details

• Sales Agreement: ATM Offering Agreement originally dated April 7, 2022, amended June 27, 2024, with H.C. Wainwright & Co., LLC as the sales agent.
• SEC filings/dates: Prospectus supplement filed April 3, 2026; Registration Statement (Form S-3, File No. 333-294503) filed March 20, 2026 and declared effective March 30, 2026.
• Legal opinion: Opinion of Norton Rose Fulbright Canada LLP regarding the legality of the common shares is filed as Exhibit 5.1 and is incorporated by reference into the Registration Statement.
• 8-K items: Reported under Item 8.01 (Other Events) with related exhibits listed under Item 9.01.

Why It Matters
Filing the prospectus supplement under the effective shelf registration enables InMed to sell common shares into the market under the ATM agreement, giving the company flexibility to raise capital as needed. For investors, this is important because future share issuances under the ATM could dilute existing holdings and affect share supply and price; the legal opinion and updated prospectus indicate the company has taken steps to ensure the offering is properly documented and legally supported.